Thursday, September 20, 2012
A working group from the Lower Anogenital Squamous Terminology (LAST) Standardization Project, an interdisciplinary project led by the College of American Pathologists (CAP) and the American Society for Colposcopy and Cervical Pathology (ASCCP), has published consensus recommendations to standardize the histopathologic terminology for squamous epithelial lesions of the lower anogenital tract associated with human papillomavirus and to guide optimal biomarker use, according to Ventana Medical Systems, a member of the Roche Group.
Ventana Medical Systems, a member of the Roche Group, has said Roche will acquire 100% of mtm laboratories, a privately-held company based in Heidelberg, Germany. mtm is a global developer in vitro diagnostics with a focus on early detection and diagnosis of cervical cancer, the largest early detection market in oncology. mtm will become part of Roche’s Tissue Diagnostics (Ventana Medical Systems) business unit. Roche will pay mtm shareholders an upfront payment of approximately $180 million as well as up to approximately $85 million upon reaching performance-related milestones.